{"id":120354,"date":"2026-08-25T15:39:19","date_gmt":"2026-08-25T15:39:19","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/120354\/"},"modified":"2026-08-25T15:39:19","modified_gmt":"2026-08-25T15:39:19","slug":"ubs-cuts-smith-nephew-target-on-competitive-threats-to-three-franchises","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/120354\/","title":{"rendered":"UBS cuts Smith &#038; Nephew target on competitive threats to three franchises"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/C114FCA063485414BDD56CBEC6F448460FEE50AF1CF4BCF92265BCB82D7F9971\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fproactive_uk_164%2Fc19213f54f5bf07fe63f1dbf7a5b2484.jpg\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"UBS cuts Smith &amp; Nephew target on competitive threats to three franchises\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> UBS cuts Smith &amp; Nephew target on competitive threats to three franchises Proactive uses images sourced from Shutterstock           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UBS has cut its price target on <a href=\"https:\/\/finance.yahoo.com\/quote\/SN.l\" data-ylk=\"slk:Smith%20%26%20Nephew%20PLC%20(LSE%3ASN);elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Smith &amp; Nephew PLC (LSE:SN)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">Smith &amp; Nephew PLC (LSE:SN)<\/a> to 1,120p from 1,300p, warning that even the medical device group&#8217;s recently reduced guidance for this year remains at risk.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The neutral rating is unchanged, with the new target implying about 3.5% upside from Monday&#8217;s close of 1,082p.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Analyst Graham Doyle said investor interest has picked up sharply following the guidance cut and the unexpected departure of the finance director.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">His conclusion is unflattering. To hit the 4% organic growth target for this year, Smith &amp; Nephew would need roughly 6% growth in the second half, which would be its second strongest such performance in a decade.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UBS forecasts 3.2% instead, and models trading profit of $1.25 billion against management&#8217;s $1.3 billion guidance.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The medium-term picture looks worse.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Management is targeting 6% to 7% organic revenue growth through 2028, against a 3.3% compound annual rate actually delivered between 2015 and 2025.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UBS models 4%, leaving its earnings forecasts 4% to 9% below consensus. The bank identifies three franchises accounting for roughly 10% of group revenue that now face fresh competition.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Santyl, a wound debridement ointment generating about $400 million a year, faces reimbursement pressure from prior authorisation requirements and a potential rival in MediWound&#8217;s EscharEx, which beat it across several endpoints in a phase two head-to-head study and could launch from 2027.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">OXINIUM, the nickel-free implant material worth roughly $100 million of US revenue, now competes with Stryker&#8217;s Triathlon Gold, a possible $20 million headwind.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">CORI, the handheld surgical robot with more than 1,100 installations and about $75 million of revenue, faces Stryker&#8217;s newly launched Mako RPS, backed by an installed base exceeding 3,000 units.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The Landmark knee platform, due in the US this quarter, is described as strategically important but unlikely to shift the numbers near-term.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UBS argues most of the anticipated benefit is already in consensus estimates.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Valuation offers some cushion, with the shares on about 12 times forward earnings and a sum-of-the-parts calculation pointing to 1,370p.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Doyle notes such portfolio businesses rarely realise that value.  <\/p>\n","protected":false},"excerpt":{"rendered":"UBS cuts Smith &amp; Nephew target on competitive threats to three franchises Proactive uses images sourced from Shutterstock&hellip;\n","protected":false},"author":2,"featured_media":120355,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[129],"tags":[58654,58652,58653,5255,223],"class_list":["post-120354","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ubs","tag-franchises","tag-graham-doyle","tag-smith-nephew","tag-target","tag-ubs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117156902538207787","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/120354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=120354"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/120354\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/120355"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=120354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=120354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=120354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}